AtaiBeckley Advances BPL-003 Into Phase 3 For Treatment-Resistant Depression

AtaiBeckley confirmed its pivotal Phase 3 program for BPL-003, a nasal spray for treatment-resistant depression, is on track to begin in Q2 2026. Progress to a pivotal trial is a constructive clinical development milestone that could be a near-term catalyst for ATAI shares, with modest stock movement likely around trial initiation and future data readouts.

Analysis

AtaiBeckley confirmed its pivotal Phase 3 program for BPL-003, a nasal spray for treatment-resistant depression, is on track to begin in Q2 2026. Progress to a pivotal trial is a constructive clinical development milestone that could be a near-term catalyst for ATAI shares, with modest stock movement likely around trial initiation and future data readouts.